Amphion Innovations Share Discussion Threads

[21trader] 02/2/2015 14:46

Stig.

When I looked at Motif before I saw the news I thought if they can get their stake worth maybe 3-5 million it would be great news so 10-15 would be a huge bonus have to wait and see.

[hoggar] 02/2/2015 13:26

The lead project rejected by the FDA was a funding issue by the patent holder Arpida Biotech to conduct extensive phase 3 trials stipulated by the FDA.

This antibacterial compound has been in existence since Arpida Biotech first patented the compound approximately fifteen years ago. Iclaprim was hailed by analysts in some quarters after completing phase 2 trials. However, 2008 saw the credit crunch and no possibility of further funding Iclaprim into phase 3 trials. A merger with Evolva was intended to take the drug forward but Evolva changed business strategy towards natural herbal compounds.

Evolva sold Iclaprim to a licensing Biotech company called Acino who in turn were bought out by Pharma Strategy Partners. Five years on, Iclaprim is now owned by an un-named US licensing Biotech company.

Motif has done a deal to hopefully raise the necessary phase 3 funds through an IPO to continue Arpida Biotechs research into Iclaprim and take it to full FDA approval.

[the stigologist] 02/2/2015 10:10

they tried this 'game' with KMK a few tears back and it had a profit warning out the gate so i don't think they will get away with it this time for an even riskier bio still 3-5 years away from commercialisation

[21trader] 02/2/2015 08:18

Company confirmed it.

02 February 2015

Amphion Innovations plc

("Amphion" or "the Company")

(LSE: AMP)

Notice of Intention to Float on AIM by Motif Bio Limited

Amphion Innovations, a developer of medical, life science, and technology businesses, is pleased to announce that Partner Company, Motif Bio Limited ("Motif"), to be renamed Motif Bio plc, has today announced its intention to raise at least GBP4 million through a placing of new ordinary shares ("Placing") and admission to trading on AIM.

Motif is a clinical stage biopharmaceutical company which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi). Discussions and negotiations with academic institutions and pharmaceutical companies are under way to build a portfolio of antibiotic candidates through licensing.

The Directors anticipate that iclaprim could be ready for commercialisation within approximately 36 months.

As of 31 December 2013, Amphion owned 32% of Motif.

Richard Morgan, CEO of Amphion, said:

"Increased drug resistance in bacteria is being recognized as a global health crisis by heads of state as well as distinguished leaders in the fields of medicine and drug development. Our world is in urgent need of novel antibiotics and Motif is poised to help address this problem. We are delighted to announce Motif's intention to float on AIM. Motif has the team in place to execute on its substantial growth opportunities and this placing and flotation on AIM will provide the capital required to progress the multiple drug development projects in Motif's exciting pipeline."

[21trader] 01/2/2015 20:43

I think tomorrow might well be more fun.

Sunday Times



THE developer of a new range of antibiotics is preparing for a London listing that could value the biotech business at up to £60m.

Motif Bio, headed by chief executive Graham Lumsden, a former vet, is in talks with potential investors ahead of a planned AIM float. It hopes to raise between £4m and £16m. If it secures the full amount, analysts suggested the company could be worth between £45m and £60m.

There is a pressing need for new antibiotics because over-prescription has led to the existing treatments losing their effectiveness.

Last year, David Cameron warned that the world could be “cast back into the dark ages of medicine” unless the problem can be tackled.

Motif’s leading potential new antibiotic is Iclaprim, which is expected to move into advanced clinical trials in the second half of this year. The testing is likely to take 18 months.

[the stigologist] 01/2/2015 19:10

Yes i think having a small stake in and then be ready to punt in and out when they have news/momentum

[21trader] 01/2/2015 17:45

It's a gamble stig but there is several different bits of news that could make the share rise a substantial amount in a day so small stakes gamble.

[21trader] 31/1/2015 18:37

isis

Guess that $40 million award which is being appealed is a massive judgement to come in their history.

Anyway said my bit now will go back to lurking.

[isis] 31/1/2015 18:31

They owe alot too and Kromek shares are being used as collateral.

Just so investors have both sides of the story.

The Awards will have to be pretty big with this lot.

[21trader] 31/1/2015 13:23

32% of this wonder what valuation this will have (US-based drug discovery company)

Amphion Innovations, a developer of medical and technology businesses, announced its part-owned US partner Motif BioSciences will merge with a private company.
The private company holds the intellectual property and rights to a clinical stage antibiotic against MRSA and multi-drug resistant bacteria.

The group added that the acquisition is conditional upon the completion of its initial public offering (IPO) on AIM in March.

Amphion, which holds 32% of Motif, said the US-based drug discovery company recently completed a pre-IPO AIM financing of £470,000.

Chief executive Richard Morgan said: "The acquisition of this clinical stage antibiotic is a game changer for Motif. As a result of change in the regulatory environment geared to encourage new antibiotics, we believe we have identified the right course for regulatory approval.

"Motif's upcoming IPO will fund this exciting plan and we believe will generate and return value to both Motif and Amphion shareholders alike."

[21trader] 31/1/2015 13:22

Been looking even closer this seriously has some value down here.

4.57 market cap

They have 12.45 million shares in Kromek which is currently 38-40p. That alone covers the market cap. (£4.73 mil at 38p bid)

You have all the awards from Datatern from Microsoft never mind Microstartegy and other companies.

They have a potential "Rodime" with their company Axcess who seems to have numerous companies using their technology without consent hence patent infringement.

[isis] 30/1/2015 16:36

That money has been paid to them and went nowhwere - that's what I said.

[21trader] 30/1/2015 16:18

I think you should believe it. It's been going on for years there should be a nice payout from it.



And from 2011 this was issued, think they have to backdate and pay costs.

Richard Morgan, CEO of Amphion, said:

"DataTern has reached settlements with over 25 companies for over $17 million in license fees using its patented Object to Relational Database Mapping technology. We will vigorously defend the validity, and intend to prove infringement, of the DataTern patents."

[isis] 30/1/2015 16:01

I had a lot of patience with these but even when they did get payouts the money went nowhere.

I'll believe it when I see it!

[21trader] 30/1/2015 15:32

isis

Have you seen how big MicroStrategy is. Massive company on Nasdaq I make it £1.8 billion. Remember AMP is under 5 million you might get a surprise here not to mention the other companies that have infringed.

"MicroStrategy, and several other defendants, infringe the '502 Patent' under the corrected claim construction. MicroStrategy sells business intelligence and analytics software platforms used by other defendants.

[the stigonomist] 30/1/2015 15:31

funny how isis changed his tune from this time last year

lolz

what other names do you post under ?

[isis] 30/1/2015 15:21

But will shareholders see any of it?

They haven't in past settlements.

All get's swallowed up in debt and monies for the Investee Companies.

[21trader] 30/1/2015 15:15

wow it's 15 years ago since Rodime won that case it was 28 million. Makes you wonder how much AMP are going to get paid next to current 4.57 mil market cap.

[the stigonomist] 30/1/2015 15:06

should be some newsflow starting on settlements one would think the respective lawyers have been thrashing things out behind closed doors

[21trader] 30/1/2015 14:44

Steadily going higher online now 2.9-3.35p no selling which is good in this market. Bit more volume and it could really go

[21trader] 30/1/2015 11:44

Yes, the 100p muted by Jumbone was just ridiculous.

But the market cap now is tiny when all the companies will have to settle with Datatern. That is what is not factored in with the current share price.

[the stigonomist] 30/1/2015 11:37

These things always look better once the pump and dump crowd is out